Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Path HoldingsBPTH EV-to-OCF is -7.51 as of Aug. 03, 2026. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Bio-Path Holdings ranks better than 64.96% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bio-Path Holdings's Enterprise Value is $2.41 Mil.
Bio-Path Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.32 Mil. Therefore, Bio-Path Holdings's EV-to-OCF for today is -7.51.
The historical rank and industry rank for Bio-Path Holdings's EV-to-OCF or its related term are showing as below:
BPTH'
s EV-to-OCF Range Over the Past 10 Years
Min: -12.99 Med: 0.01 Max: 0.32
Current: -7.51
During the past 13 years, the highest EV-to-OCF of Bio-Path Holdings was 0.32. The lowest was -12.99. And the median was 0.01.
BPTH's EV-to-OCF is ranked better than 64.96% of 1410
companies
in the Biotechnology industry
Industry Median: -3.23
vs BPTH: -7.51
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Path Holdings's PE Ratio (TTM) for today is calculated as:
Bio-Path Holdings's share price for today is $0.038.
Bio-Path Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio-Path Holdings EV-to-OCF Related Terms
Bio-Path Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Bio-Path Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Path Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's EV-to-OCF falls into.
Bio-Path Holdings's current Enterprise Value is $2.41 Mil.
Bio-Path Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (BPTH) has a EV-to-OCF of -7.51 as of Aug. 03, 2026. According to the industry distribution chart, Bio-Path Holdings ranks #494 out of 1410 companies in the Biotechnology industry, placing it in the top 35%.
Is Bio-Path Holdings' EV-to-OCF too high?
Bio-Path Holdings' current EV-to-OCF is -7.51. Based on the distribution chart, Bio-Path Holdings ranks #494 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint.
How does Bio-Path Holdings' EV-to-OCF compare to AZTR and CLDI?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #494 out of 1410 companies for EV-to-OCF. This puts Bio-Path Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Bio-Path Holdings's current EV-to-OCF is -7.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current EV-to-OCF of -7.51. The current EV-to-OCF is -7.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current EV-to-OCF is -7.51 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 
